HUP0003546A3 - Compositions for administering taxanes orally to human patients - Google Patents

Compositions for administering taxanes orally to human patients

Info

Publication number
HUP0003546A3
HUP0003546A3 HU0003546A HUP0003546A HUP0003546A3 HU P0003546 A3 HUP0003546 A3 HU P0003546A3 HU 0003546 A HU0003546 A HU 0003546A HU P0003546 A HUP0003546 A HU P0003546A HU P0003546 A3 HUP0003546 A3 HU P0003546A3
Authority
HU
Hungary
Prior art keywords
compositions
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
HU0003546A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of HUP0003546A2 publication Critical patent/HUP0003546A2/hu
Publication of HUP0003546A3 publication Critical patent/HUP0003546A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0003546A 1997-05-27 1998-04-22 Compositions for administering taxanes orally to human patients HUP0003546A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27

Publications (2)

Publication Number Publication Date
HUP0003546A2 HUP0003546A2 (hu) 2002-11-28
HUP0003546A3 true HUP0003546A3 (en) 2002-12-28

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003546A HUP0003546A3 (en) 1997-05-27 1998-04-22 Compositions for administering taxanes orally to human patients

Country Status (23)

Country Link
EP (1) EP0994706B1 (hu)
JP (1) JP2002500667A (hu)
KR (1) KR100615783B1 (hu)
CN (2) CN1550231A (hu)
AR (1) AR012731A1 (hu)
AT (1) ATE308365T1 (hu)
AU (1) AU7130098A (hu)
BR (1) BR9809694A (hu)
CA (1) CA2290446C (hu)
CZ (1) CZ9904244A3 (hu)
DE (1) DE69832173T2 (hu)
DK (1) DK0994706T3 (hu)
ES (1) ES2247690T3 (hu)
HK (1) HK1026637A1 (hu)
HU (1) HUP0003546A3 (hu)
IL (2) IL132992A0 (hu)
NO (1) NO995812L (hu)
PL (1) PL337064A1 (hu)
RU (1) RU2205005C2 (hu)
SK (1) SK157599A3 (hu)
UA (1) UA74767C2 (hu)
WO (1) WO1998053811A1 (hu)
ZA (1) ZA984268B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998058927A1 (en) * 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1189637B1 (en) 1999-05-17 2006-08-23 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
BR0015149A (pt) * 1999-10-27 2002-10-29 Baker Norton Pharma Método e composições para administração de taxanos oralmente a pacientes humanos
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
WO2002064132A2 (en) * 2001-01-18 2002-08-22 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1623706A3 (en) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomic dosing of taxanes for inhibiting tumor growth
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
AU2010256677A1 (en) * 2009-06-02 2012-01-12 Nikan Pharmaceuticals, Llc Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
WO2022195017A1 (en) * 2021-03-17 2022-09-22 Dompe' Farmaceutici Spa C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
DK0569380T3 (da) * 1991-01-11 1997-12-22 Glaxo Lab Sa Acridinderivater
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
PL187579B1 (pl) * 1994-07-26 2004-08-31 Indena Spa Nowe półsyntetyczne taksany, sposób wytwarzania półsyntetycznych taksanów, nowe związki pośrednie, nowe półsyntetyczne seko-taksany, sposób wytwarzania półsyntetycznych seko-taksanów i przeciwnowotworowe kompozycje farmaceutyczne
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) * 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
JP2000512997A (ja) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー 薬物耐性および多薬物耐性調節物質
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1067908B9 (en) * 1998-04-01 2007-01-24 Jagotec Ag Taxane microemulsions

Also Published As

Publication number Publication date
CA2290446A1 (en) 1998-12-03
WO1998053811A1 (en) 1998-12-03
EP0994706B1 (en) 2005-11-02
RU2205005C2 (ru) 2003-05-27
EP0994706A4 (en) 2001-05-16
ES2247690T3 (es) 2006-03-01
DE69832173D1 (de) 2005-12-08
CN1550231A (zh) 2004-12-01
AR012731A1 (es) 2000-11-08
EP0994706A1 (en) 2000-04-26
JP2002500667A (ja) 2002-01-08
IL132992A0 (en) 2001-03-19
NO995812D0 (no) 1999-11-26
DE69832173T2 (de) 2006-08-03
KR100615783B1 (ko) 2006-08-25
PL337064A1 (en) 2000-07-31
NO995812L (no) 2000-01-25
SK157599A3 (en) 2002-10-08
CZ9904244A3 (cs) 2001-10-17
BR9809694A (pt) 2000-10-03
ATE308365T1 (de) 2005-11-15
ZA984268B (en) 1999-06-23
KR20010013025A (ko) 2001-02-26
AU7130098A (en) 1998-12-30
UA74767C2 (en) 2006-02-15
DK0994706T3 (da) 2006-03-06
IL132992A (en) 2006-08-20
CA2290446C (en) 2008-01-29
HUP0003546A2 (hu) 2002-11-28
HK1026637A1 (en) 2000-12-22
CN1261275A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
HUP0002512A3 (en) Medicinal compositions for application to mucosa
IL118637A0 (en) Oral pharmaceutical compositions of S(+)-ibuprofen
HUP0104316A3 (en) Substituted benzopyran analogs for the treatment of inflammation and pharmaceutical compositions containing them
IL115097A0 (en) Pharmaceutical compositions adapted for oral administration
HUP0202495A3 (en) Stable medicinal compositions for oral use
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
HK1149719A1 (en) Ciclesonide contained pharmaceutical composition for application to mucosa
HUP0003546A3 (en) Compositions for administering taxanes orally to human patients
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
IL118636A0 (en) Oral pharmaceutical compositions of s(+)-etodolac
HUP0203303A3 (en) Compositions for administering taxanes orally to human patients
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0201667A2 (en) Oral form of administration
HUP9801925A3 (en) Use of sodium-hydrogen-exchange-inhibitors for producing pharmaceutical compositions treating diseases caused by protozoons
EP1210935A4 (en) DRUGS FOR ORAL USE
HUP0200311A3 (en) Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions
IL131355A0 (en) Use of pivagabin to prepare pharmaceutical compositions
HUP0000569A3 (en) Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
AU784159C (en) Method and compositions for administering taxanes orally to human patients
EP1188440A4 (en) MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
HU9700079D0 (en) Topical compositions for the treatment of skin disease
HUP9903735A3 (en) Use of indazolo derivatives for producing pharmaceutical compositions for treatment heart failure
AU4491697A (en) Compositions of therapeutic agents suitable for oral administration
HUP0101012A3 (en) Pharmaceutical composition for oral administration

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DR. PALAGYI TIVADAR, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU

Representative=s name: SZENTPETERI ZSOLT, S.B.G. & K. SZABADALMI UEGY, HU

FH92 Termination of representative

Representative=s name: DR. PALAGYI TIVADAR, DANUBIA SZABADALMI ES VED, HU

HC9A Change of name, address

Owner name: IVAX RESEARCH, INC., US

Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished